hodgkin's lymphoma
Showing NaN - NaN of 11
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma Trial in Boston (GCSF, meloxicam, Placebo)
Completed
- Non-Hodgkin's Lymphoma
- +3 more
- GCSF
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
May 15, 2020
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma Trial in United States
Completed
- Relapsed or Refractory Lymphoproliferative Malignancies
- +4 more
- Pralatrexate Injection
- +3 more
-
Los Angeles, California
- +14 more
Dec 27, 2019
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma Trial in Boston (drug, radiation, biological)
Completed
- Non-Hodgkin's Lymphoma
- +4 more
- Fludarabine
- +3 more
-
Boston, Massachusetts
- +2 more
Dec 29, 2018
Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia Trial in United States (Tacrolimus (ARM with Methotrexate),
Completed
- Acute Leukemia
- +8 more
- Tacrolimus (ARM with Methotrexate)
- +7 more
-
Duarte, California
- +29 more
Jan 2, 2019
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma Trial in Boston (Busulfan (conditioning for AUTO
Completed
- Diffuse, Large B-Cell, Lymphoma
- +6 more
- Busulfan (conditioning for AUTO transplant)
- +11 more
-
Boston, Massachusetts
- +1 more
Jan 19, 2017
AML, ALL, CLL Trial in Boston (Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF)
Completed
- AML
- +8 more
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jul 14, 2016
Hodgkin's Lymphoma Trial in Worldwide (Panobinostat, Placebo)
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia Trial in United States (VCL-CB01,
Completed
- Acute Lymphoblastic Leukemia
- +5 more
- VCL-CB01
- Phosphate-buffered Saline (PBS)
-
Tucson, Arizona
- +21 more
Jul 31, 2013
Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Completed
- Hodgkin's Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jul 15, 2013
Hematologic Malignancy, AML, ALL Trial in Boston (CD+8 T cell depletion)
Completed
- Hematologic Malignancy
- +6 more
- CD+8 T cell depletion
-
Boston, Massachusetts
- +1 more
Mar 15, 2012